Coloplast Statistics
Total Valuation
Coloplast has a market cap or net worth of 24.90 billion. The enterprise value is 27.94 billion.
| Market Cap | 24.90B |
| Enterprise Value | 27.94B |
Important Dates
The next estimated earnings date is Tuesday, February 4, 2025.
| Earnings Date | Feb 4, 2025 |
| Ex-Dividend Date | Dec 6, 2024 |
Share Statistics
| Current Share Class | n/a |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +4.36% |
| Shares Change (QoQ) | -0.04% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | 141.36M |
Valuation Ratios
The trailing PE ratio is 32.95.
| PE Ratio | 32.95 |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 23.64, with an EV/FCF ratio of 116.77.
| EV / Earnings | 36.98 |
| EV / Sales | 7.41 |
| EV / EBITDA | 23.64 |
| EV / EBIT | 27.42 |
| EV / FCF | 116.77 |
Financial Position
The company has a current ratio of 1.02, with a Debt / Equity ratio of 1.26.
| Current Ratio | 1.02 |
| Quick Ratio | 0.62 |
| Debt / Equity | 1.26 |
| Debt / EBITDA | 2.67 |
| Debt / FCF | 14.14 |
| Interest Coverage | 9.19 |
Financial Efficiency
Return on equity (ROE) is 28.67% and return on invested capital (ROIC) is 11.80%.
| Return on Equity (ROE) | 28.67% |
| Return on Assets (ROA) | 9.49% |
| Return on Capital (ROIC) | 11.80% |
| Revenue Per Employee | 242,964 |
| Profits Per Employee | 45,411 |
| Employee Count | 16,639 |
| Asset Turnover | 0.56 |
| Inventory Turnover | 2.44 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -5.67% in the last 52 weeks. The beta is 0.33, so Coloplast's price volatility has been lower than the market average.
| Beta (5Y) | 0.33 |
| 52-Week Price Change | -5.67% |
| 50-Day Moving Average | 123.20 |
| 200-Day Moving Average | 125.78 |
| Relative Strength Index (RSI) | 21.06 |
| Average Volume (20 Days) | 162 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Coloplast had revenue of 4.04 billion and earned 755.59 million in profits. Earnings per share was 3.36.
| Revenue | 4.04B |
| Gross Profit | 2.73B |
| Operating Income | 1.09B |
| Pretax Income | 956.45M |
| Net Income | 755.59M |
| EBITDA | 1.23B |
| EBIT | 1.09B |
| Earnings Per Share (EPS) | 3.36 |
Balance Sheet
The company has 117.86 million in cash and 3.38 billion in debt, giving a net cash position of -3.27 billion.
| Cash & Cash Equivalents | 117.86M |
| Total Debt | 3.38B |
| Net Cash | -3.27B |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 2.68B |
| Book Value Per Share | 11.92 |
| Working Capital | 35.90M |
Cash Flow
In the last 12 months, operating cash flow was 413.69 million and capital expenditures -174.39 million, giving a free cash flow of 239.30 million.
| Operating Cash Flow | 413.69M |
| Capital Expenditures | -174.39M |
| Free Cash Flow | 239.30M |
| FCF Per Share | n/a |
Margins
Gross margin is 67.59%, with operating and profit margins of 27.04% and 18.69%.
| Gross Margin | 67.59% |
| Operating Margin | 27.04% |
| Pretax Margin | 23.66% |
| Profit Margin | 18.69% |
| EBITDA Margin | 30.30% |
| EBIT Margin | 27.04% |
| FCF Margin | 5.92% |
Dividends & Yields
This stock pays an annual dividend of 2.41, which amounts to a dividend yield of 2.14%.
| Dividend Per Share | 2.41 |
| Dividend Yield | 2.14% |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | 93.43% |
| Buyback Yield | -4.36% |
| Shareholder Yield | -2.22% |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Coloplast has an Altman Z-Score of 5.4.
| Altman Z-Score | 5.4 |
| Piotroski F-Score | n/a |